Companies in the News

Vividion Secures $82 Million to Advance Its Lead Programs into the Clinic

Vividion Therapeutics snagged $82 million in an oversubscribed Series B funding round to bolster its cash holdings that will be used to advance the San Diego-based company’s lead programs into the clinic and broaden the early-stage pipeline of therapeutics against previously intractable drug targets. The latest financing round comes a little more than a year after the company secured $101 million from Celgene last year to develop unique small molecule therapies for a range of oncology, inflammatory and neurodegenerative indications. Vividion launched in 2017. Diego Miralles, Vividion’s chief executive officer, said the company now has more than $165 million in cash. The funding, coupled with

Gritstone Oncology Announces Clinical Acceleration of “Off-The-Shelf” Personalized Neoantigen Immuno

EMERYVILLE, Calif., April 22, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), an immuno-oncology company developing tumor-specific cancer immunotherapies to fight multiple cancer types, today announced that following feedback from the U.S. Food and Drug Administration (FDA) the SLATE Phase 1 clinical study may be accelerated by up to six months from the company’s prior expectations by leveraging pre-clinical data generated for the original GRANITE Investigational New Drug (IND) application. “Both SLATE and GRANITE use the same immunogenic viral vector system to deliver tumor-specific neoantigens (TSNA) to patients with the objective of driving a powerful and sustained T-cel

BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-33

Phase 1 results and new translational data supporting the development of BTRX-335140 for neurobehavioral disorders presented at the Kappa Therapeutics 2019 Conference San Francisco – April 1, 2019 – BlackThorn Therapeutics, a neurobehavioral health company leveraging its proprietary computational psychiatry platform to develop targeted therapeutics, today announced positive Phase 1 results and new translational data supporting development of BTRX-335140, the company’s selective kappa opioid receptor (KOR) antagonist, for neurobehavioral disorders. The findings were presented at the Kappa Therapeutics 2019 Conference that took place March 28 – 30 in Seattle, Washington. The KOR system is an i